The present announcement does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In the interests of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process designation "open process" (Section IV.1.1) used in the context of the present announcement text is owed to the specifications of the announcement form. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is by law or procurement ordinances is not mandatory. It is a framework agreement with the option to join, which relates to various active ingredients.

The subject of the contract are drugs that contain the active ingredient combination olmesartan, amlodipine and hydrochlorothiazide.